Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.34 |
| ▸ | DNMT3L | Q9UJW3 | 4/20 | 0.34 |
| ▸ | DNMT3A | Q9Y6K1 | 4/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161376 | 0.93 | P2RY12 (0.39) | HRH3TERTP2RY12MCHR1KCNH2 | |
| SCHEMBL9923181 | 0.92 | P2RY12 (0.39) | HRH3TERTP2RY12KCNH2 | |
| SCHEMBL14113551 | 0.90 | HRH3 (0.39) | HRH3TERTP2RY12MCHR1KCNH2 | |
| SCHEMBL13182891 | 0.90 | RAD52 (0.40) | — | |
| SCHEMBL9923185 | 0.89 | P2RY12 (0.37) | HRH3TERTP2RY12MCHR1KCNH2 | |
| SCHEMBL9922927 | 0.88 | HRH3 (0.36) | HRH3TERTP2RY12CTNNB1TCF7L2 | |
| SCHEMBL9923193 | 0.88 | P2RY12 (0.37) | HRH3P2RY12KCNH2 | |
| SCHEMBL12177095 | 0.88 | P2RY12 (0.34) | P2RY12KIT | |
| SCHEMBL9922387 | 0.88 | HRH3 (0.42) | HRH3TERTP2RY12CTNNB1TCF7L2 | |
| SCHEMBL13638373 | 0.87 | ATM (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HRH3 1858/4885TERT 2585/4885DNMT1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.